CollPlant Biotechnologies Ltd. has announced a significant development that could enhance its technological capabilities. The company revealed that its subsidiary, LightSolver, has secured a grant of approximately $1.8 million from the Israel Innovation Authority (IIA). This funding is aimed at advancing the development of LightSolver's Laser Processing Unit (LPU), a cutting-edge, all-optical computing platform.

The grant represents a vote of confidence in the potential of LightSolver's technology, which is designed to address complex computational challenges in various fields, including artificial intelligence and high-performance computing. The funding will support the maturation of the LPU platform and its journey toward commercialization.

Background

CollPlant Biotechnologies Ltd. operates in the orthopedic, prosthetic, and surgical appliances and supplies industry, as classified under SIC 3842. The company trades on the Nasdaq under the ticker symbol CLGN. CollPlant focuses on developing innovative technologies, including proprietary plant-derived recombinant human collagen and advanced computing solutions through its subsidiary, LightSolver.

What the Filing Says

In the recent filing, CollPlant stated, "On November 5, 2026, CollPlant Biotechnologies Ltd. issued a press release entitled 'LightSolver Secures ~$1.8 Million Grant from Israel’s Innovation Authority to Advance its Laser Processing Unit (LPU).'" The grant is intended to enhance the capabilities of the LPU and is expected to contribute significantly to the Israeli economy.

Impact

This development may have a considerable impact on various stakeholders, including investors, customers, and competitors in the orthopedic and surgical appliance industry. The grant will enable LightSolver to enhance its technological offerings and potentially attract further partnerships and collaborations, particularly in high-performance computing sectors.

What's Next

Subject to shareholder approval, CollPlant intends to change its name to OptiPhi Computing Ltd. and its Nasdaq ticker symbol from CLGN to OPHI. Further details on the timeline for these changes were not disclosed in the filing.